PreprintPDF Available

Reversal of Epigenetic Age with Diet and Lifestyle in a Pilot Randomized Clinical Trial

Authors:
  • Providence Research Network

Abstract and Figures

Manipulations to set back biological age and extend lifespan in animal models are well established, and translation to humans has begun. The length of human life makes it impractical to evaluate results by plotting mortality curves, so surrogate markers of age have been suggested and, at present, the best established surrogates are DNA methylation clocks. Herein we report on a randomized, controlled clinical trial designed to be a first step in evaluating the effect of a diet and lifestyle intervention on biological age. Compared to participants in the control group (n=20), participants in the treatment group tested an average 3.23 years younger at the end of the eight-week program according to the Horvath DNAmAge clock (p=0.018). Those in the treatment group (n=18) tested an average 1.96 years younger at the end of the program compared to the same individuals at the beginning with a strong trend towards significance (p=0.066 for within group change). This is the first such trial to demonstrate a potential reversal of biological age. In this study, the intervention was confined to diet and lifestyle changes previously identified as safe to use. The prescribed program included multiple components with documented mechanistic activity on epigenetic pathways, including moderate exercise, breathing exercises for stress, and a diet rich in methyl donor nutrients and polyphenols.
Content may be subject to copyright.
Reversal of Epigenetic Age with Diet and Lifestyle in a Pilot Randomized Clinical
Trial
Authors: Kara N. Fitzgerald1, Romilly Hodges2, Douglas Hanes3, Emily Stack4, David Cheishvili5, Moshe
Szyf6, Janine Henkel7, Melissa W. Twedt8, Despina Giannopoulou9, Josette Herdell10, Sally Logan11,
Ryan Bradley12
This clinical trial was carried out at the Helfgott Research Institute at the National University of Natural
Medicine, 2220 SW 1st Ave, Portland, OR 97201, USA
Corresponding author:
Kara N. Fitzgerald
27 Glen Road, 4th Floor, Sandy Hook, CT 06482 USA
Tel: +1-203-304-9502
Email: kf@drkarafitzgerald.com
Running title: Clinical Trial: Reversing Epigenetic Age with Lifestyle
1 27 Glen Road, 4th Floor, Sandy Hook, CT 06482 USA. kf@drkarafitzgerald.com
2 27 Glen Road, 4th Floor, Sandy Hook, CT 06482 USA. romilly@drkarafitzgerald.com
3 Helfgott Research Institute, National University of Natural Medicine, 2220 SW 1st Ave, Portland, OR 97201,
USA. dhanes@nunm.edu
4 Helfgott Research Institute, National University of Natural Medicine, 2220 SW 1st Ave, Portland, OR 97201,
USA. estack@nunm.edu
5 HKG Epitherapeutics (Hong Kong); Department of Molecular Biology, Ariel University, Israel; Gerald Bronfman
Department of Oncology, McGill University, Montreal, Quebec, Canada. david.cheishvili@mcgill.ca
6 Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6 Canada.
moshe.szyf@mcgill.ca
7 1526 Wildflower Ct., Gardnerville, NV 89410, USA. janinemhenkel@gmail.com
8 512 W. Lancaster Ave., Wayne, PA 19087, USA. melissa@keystonenutrition.net
9 8 North Tenter Street, Flat 2, London E1 8DL, UK. despina2010@gmail.com
10 3183 S. Bonnel Rd. Coeur d’Alene, ID 83814. fxmednutrition@gmail.com
11 25 Kingston Road, Kensington CA 94707. sallylogan87@gmail.com
12 Helfgott Research Institute, National University of Natural Medicine, 2220 SW 1st Ave, Portland, OR 97201,
USA. Division of Preventive Medicine, University of California, San Diego, 9550 Gilman Drive, La Jolla, CA
92023. rbradley@nunm.edu
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
SUMMARY
Manipulations to set back biological age and extend lifespan in animal models are well established, and
translation to humans has begun. The length of human life makes it impractical to evaluate results by
plotting mortality curves, so surrogate markers of age have been suggested and, at present, the best
established surrogates are DNA methylation clocks. Herein we report on a randomized, controlled clinical
trial designed to be a first step in evaluating the effect of a diet and lifestyle intervention on biological
age. Compared to participants in the control group (n=20), participants in the treatment group tested an
average 3.23 years younger at the end of the eight-week program according to the Horvath DNAmAge
clock (p=0.018). Those in the treatment group (n=18) tested an average 1.96 years younger at the end of
the program compared to the same individuals at the beginning with a strong trend towards significance
(p=0.066 for within group change). This is the first such trial to demonstrate a potential reversal of
biological age. In this study, the intervention was confined to diet and lifestyle changes previously
identified as safe to use. The prescribed program included multiple components with documented
mechanistic activity on epigenetic pathways, including moderate exercise, breathing exercises for stress,
and a diet rich in methyl donor nutrients and polyphenols.
1 INTRODUCTION
Advanced age is the largest risk factor for impaired mental and physical function and many non-
communicable diseases including cancer, neurodegeneration, type 2 diabetes, and cardiovascular disease
(Jin et al., 2015; Sen et al., 2016). The growing health-related economic and social challenges of our
rapidly aging population are well recognized and affect individuals, their families, health systems and
economies. Considering economics alone, using the Future Elderly Model, Goldman showed that
delaying aging by 2.2 years (with associated extension of healthspan) could save $7 trillion over fifty
years. This broad approach was identified to be a much better investment than disease-specific spending
(Goldman, 2017). Thus, if interventions can be identified that extend healthspan even modestly, benefits
for public health and healthcare economics will be substantial.
DNA methylation is the addition of a methyl group to cytosine residues at selective areas on a
chromosome (e.g. CpG islands, shelf/shore, exons, open sea). Methylation constitutes the best-studied,
and likely most resilient of many mechanisms controlling gene expression (Li & Zhang, 2014). Unique
among epigenetic markers, DNA methylation can readily and cheaply be mapped from tissue samples. Of
20+ million methylation sites on the human genome, there are a few thousand at which methylation levels
are tightly correlated with age. Currently, the best biochemical markers of an individual’s age are all
based on patterns of methylation (Horvath & Raj, 2018). This has led some researchers to propose that
aging itself has its basis in epigenetic changes (including methylation changes) over time (Field et al.,
2018; Johnson et al., 2012; Mitteldorf, 2013; Rando & Chang, 2012).
As of this writing, the best-studied methylation-based clock is the multi-tissue DNAmAge clock
(Horvath, 2013). At the time this study design was approved, there were few viable alternatives.
Horvath’s DNAmAge clock predicts all-cause mortality and multiple morbidities better than
chronological age. Methylation clocks (including DNAmAge) are based on systematic methylation
changes with age, with about 60% of CpG sites losing methylation with age and 40% gaining
methylation. This is distinct from stochastic changes, “methylation drift”, unpredictable changes which
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
vary among individuals and cell-by-cell within individuals. Systematic methylation changes include
hypermethylation in promotor regions of tumor suppressor genes (inhibiting expression) and
hypomethylation promoting inflammatory cytokines (promoting expression). Saliva can be considered a
good source of high-quality DNA, containing both white blood cells and buccal cells, and is a suitable
tissue type to be assessed for the DNAmAge clock (Horvath, 2013; Langie et al., 2017).
The dietary recommendations employed as part of the treatment protocol for this study were based largely
on biochemistry and generalized measures of health, because few dietary associations with the
DNAmAge clock have yet been established. A modest, but significant, reduction in DNAmAge in
individuals consuming a non-specific lean meat, fish and plant-based diet (as measured by blood
carotenoids) has been observed (Quach et al., 2017). It is possible that changes of a greater magnitude
require a more targeted approach. The dietary intervention used here was also plant-centered, but
including a high intake of nutrients that are substrates or cofactors in methylation biosynthetic pathways
(e.g. containing folate, betaine), ten-eleven translocation demethylase cofactors and modulators (e.g.
alpha ketoglutarate, vitamin C and vitamin A) (Hore, 2017) and polyphenolic modulators of DNA methyl
transferases (DNMT) (e.g. curcumin, epigallocatechin gallate (EGCG), rosmarinic acid, quercetin,
luteolin). It also included limited nutrient-dense animal proteins (e.g. liver, egg). The diet restricted
carbohydrates and included mild intermittent fasting, both designed to lower glycemic cycling. The diet
was supplemented daily with a fruit and vegetable powder, also rich in polyphenolic modulators of
DNMT activity , and a probiotic providing 40 million CFU of Lactobacillus plantarum 299v. L.
plantarum has been shown to be a folate producer in the presence of para aminobenzoic acid (PABA)
(Sybesma et al., 2003); it also has been demonstrated to alter gene expression (Hariri et al., 2015).
Lifestyle guidance in this study included a minimum of 30 minutes of exercise per day, at least 5 days per
week at an intensity of 60-80 percent of maximum perceived exertion. Exercise is well-known to be
broadly beneficial for almost every aspect of health and has been shown to extend mean lifespan in
animal models. Exploration of the effect of exercise on the methylome has recently begun. For example,
regular tai chi practice was associated with slowing of age-related DNA methylation losses in 500 women
(Ren et al., 2012). In another study of 647 women, a lifelong history of exercise was associated with a
similar endpoint (White et al., 2013). These results were not reported in terms of the Horvath clock,
because it had not yet been developed. One systematic review of human studies found that regular, daily
physical activity was associated with lower blood levels of homocysteine, which when elevated, suggests
an insufficiency of methylation capacity (e Silva & da Mota, 2014). Excessive exercise may accelerate
methylation aging, but this danger has only been observed in elite, competitive athletes (Spólnicka et al.,
2018).
Twice-daily breathing exercises that elicit the Relaxation Response were prescribed for stress reduction. It
was recently demonstrated that 60 days of relaxation practice designed to elicit the Relaxation Response,
20 minutes twice per day, could significantly reduce DNAmAge as measured by the Zbie -Piekarska
clock in their group of healthy participants (though not in their ‘patient’ group) (Pavanello et al., 2019).
Almost a quarter of the DNAmAge CpG sites (85/353) are located in glucocorticoid response elements,
pointing to a likely relationship between stress and accelerated aging. Cumulative lifetime stress has been
shown to be associated with accelerated aging of the methylome (Zannas et al., 2015). Zannas et al. also
reported that dexamethasone, a glucocorticoid agonist, can advance the DNAmAge clock and induce
associated transcriptional changes. Dexamethasone-regulated genes showed enriched association of
aging-related diseases, including coronary artery disease, arteriosclerosis and leukemias. Other findings
include that PTSD contributes to accelerated methylation age (Wolf et al., 2016); and that greater infant
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
distress (lack of caregiver contact) is associated with an underdeveloped, younger epigenetic age (Moore
et al., 2017).
This study aimed to optimize sleep, with a recommendation for at least seven hours nightly. Seven hours
is generally considered to be healthy (Panel et al., 2015), but the limited data on accelerated aging only
relates to extremes of sleep deprivation. A (presumably transient) effect of sleep deprivation on genome-
wide methylation patterns in blood has been demonstrated (Nilsson et al., 2016). Acceleration of the
DNAmAge clock has been associated with insomnia in a sample of 2078 women (Carroll et al., 2017).
Carskadon et al (2019) found an association between poor quality / fewer hours of sleep with age
acceleration in a small sample of 12 female college students.
This multimodal (“systems”) intervention is reflective of a clinically-used approach that combines
individual interventions, each of which carry evidence of favorable influence on the DNA methylome and
of which several authors of this study have clinical experience of health benefits. Such interventions
likely produce synergistic effects and reduce the possibility of negative effects from one disease-
promoting input canceling out the benefits of another health-promoting input. Dietary and lifestyle
interventions, as used here, target upstream influences that are generally considered safe, even over the
long term.
By design, an important endpoint of this study was to be Horvath’s DNAmAge clock, to see if it could be
potentially slowed or reversed. This is to say we have tentatively accepted the hypothesis that the
methylation pattern from which the DNAmAge clock is computed is a driver of aging (and the chronic
diseases of aging), thus we expect that attempting to directly influence the DNA methylome using diet
and lifestyle to set back DNAmAge will lead to a healthier, more “youthful” metabolism. To date, one
small pilot study (Fahy et al., 2019) has been reported to have set back the DNAmAge clock over the
course of 12 months by 1.5 (plus the one-year duration of the study) years in humans, using a
combination of growth hormone, metformin, DHEA and two dietary supplements. Herein we report
comparable initial results based on diet and lifestyle interventions employed for eight weeks (preceded by
a one-week washout period).
2 RESULTS
2.1 Methylation clock setback
Compared to participants in the control group (n=20), participants in the treatment group scored an
average 3.23 years younger at the end of the eight-week program according to the Horvath DNAmAge
clock (p=0.018). Those in the treatment group (n=18) scored an average 1.96 years younger, at the end of
the program compared to the same individuals at the beginning with a strong trend towards significance
(p=0.066 for within group change). Control participants scored an average of 1.27 years older at the end
of the study period, though this within-group increase was not statistically significant (p= 0.153).
Comparison of DNAmAge change between treatment and control groups is shown in Figure 1 whereas
within group changes for the treatment group are shown in Figure 2.
In both treatment and control groups, global average methylation stayed the same over the course of the
study, with no net increase or decrease in the 353 sites that compose the Horvath clock.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
3 DISCUSSION
3.1 Significance of Results
The significance of these findings is multi-factorial, but primarily as the first demonstration of potential
reversal of epigenetic age in a randomized, controlled clinical trial, accounting for any normal variability
in epigenetic methylation. Secondarily, this is the first report of a diet and lifestyle intervention reducing
biologic aging. Notably, the scale of potential reduction, while modest in magnitude, may correlate with
meaningful socioeconomic benefits, and appears to have the potential to be broadly achievable.
Published in the fall of 2019, the TRIIM study (Fahy et al., 2019) was the first demonstration of a set of
interventions setting back the flagship Horvath clock DNAmAge (Horvath, 2013). In TRIIM, a one-year
regimen of daily injection of growth hormone plus one prescription drug and three nutritional
supplements was shown to set back the DNAmAge clock by 1.5 years in 9 middle-aged men (plus the 1-
year study duration = 2.5 years). In the present study, age set-back was achieved in eight weeks, using
less expensive, less invasive, and otherwise generally beneficial interventions known to have mechanistic
plausibility for affecting methylation pathways.
3.2 Targeting Epigenetics with Diet
The seminal work of Waterland and Jirtle (Waterland & Jirtle, 2003) in the Agouti mouse model marked
a defining point in our understanding that nutrition elements could so affect DNA methylation marks as to
silence gene expression and dramatically alter phenotype. The power of nutrition to bring about
transformative phenotypic changes has held up over the intervening years, most strongly in animal
studies, but also in some limited human trials (Waterland & Jirtle, 2003). Both TRIIM and the present
study were able to effect changes on the DNA methylome without extra-dietary supplementation of
known methyl donor nutrients (e.g., folate, vitamin B12, choline, SAMe or betaine) Illustrating a far-
reaching regulatory network on DNA methylation and representing a departure from previous studies that
manipulated DNA methylation more directly with extra-dietary supplemental folate, B12 and other
methyl donor nutrients (Pauwels et al., 2017; Sae-Lee et al., 2018; Waterland & Jirtle, 2003; Zhong et al.,
2017).
3.3 Rationale for Not Using Supplemental Methyl Donor Nutrients
In designing the present study, extra-dietary supplementation of methyl donor nutrients was specifically
avoided because a growing body of epidemiological evidence indicates potential long-term risks, to which
the short-term studies were not sensitive. Although overall data are mixed, and certain conditions (e.g.
pregnancy, macrocytic anemia, hyperhomocysteinemia, dietary limitations) often require extra-dietary
supplementation, several trials have found a positive association between methyl donor supplementation
and increased cancer risk: Published long-term follow up on 2,524 participants in the B-PROOF trial
which assessed the effect of 2-3 years of daily supplementation with 400 mcg folic acid and 500 mcg
vitamin B12 found an increased risk of overall cancer (HR 1.25, 95% CI 1.00-1.53), p=0.05) and
colorectal cancer in particular (HR 1.77, 95% CI 1.08-2.90, p=0.02) (Oliai Araghi et al., 2019). A meta-
analysis of 2 trials in Norway similarly reported that 800 mcg folic acid plus 400 mg vitamin B12 daily
was associated with increased cancer outcomes and all-cause mortality (Ebbing et al., 2009). In contrast,
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
dietary folate intake from food was found to be inversely associated with non-muscle-invasive bladder
cancer progression in a study that also found higher recurrence for folic acid intake (Tu et al., 2018), and
baseline dietary folate intake was inversely associated with prostate cancer risk in a trial that subsequently
identified an increased risk of prostate cancer in the treatment arm that received 1 mg folic acid per day
for 10 years (Figueiredo et al., 2009). Also relevant is the demonstration, albeit in a small study, adding
dietary supplements of folic acid, vitamin B6 and vitamin B12 to a vitamin D plus calcium intervention
increased biological aging (sex-adjusted odds ratio 5.26 vs vitamin D plus calcium alone) during a 1-year
intervention (Obeid et al., 2018).
3.5 Polyphenols as Selective DNA Modulators
The DNAmAge clock is computed from some sites that increase and others that decrease methylation
with age, so a net methylation increase would not necessarily be beneficial. Since this study targeted a
healthy methylation pattern, not limited to increased methylation, the prescribed diet was rich in TET
demethylase-associated nutrients (Hore, 2017) and specific plant polyphenols known to selectively
regulate DNMT activity in addition to food-sourced methyl donors. It may be that these compounds assist
in elevating methylation substrate and cofactor support from a risky ‘blunt instrument’ to ‘precision
surgery’ on the DNA methylome by regulating where methyl groups are applied and removed.
3.6 Is Methylation Age Setback a Proxy for Reversed Senescence?
The DNA methylation aging hypothesis has been well-articulated, though it not achieved universal
acceptance. The idea that aging (like developmental biology) is rooted in epigenetics was first discussed
around 2012 (Johnson et al., 2012; Mitteldorf, 2013; Rando & Chang, 2012), and has continued to gain
adherents since (Barja, 2019; Horvath & Raj, 2018; Pal & Tyler, 2016). There may now be an emerging
consensus that aging is driven by epigenetics (Sen et al., 2016) and that an epigenetic assault on aging is a
feasible way to reduce multi-morbidities in an aging population (Jin et al., 2015). Even authors who have
a historic commitment to a view of aging based in accumulated damage are acknowledging the practical
potential of age reversal via epigenetics (Boyd-Kirkup et al., 2013; Hayano et al., 2019; Kane & Sinclair,
2019; West et al., 2019).
It is not yet fully established whether interventions that slow or reverse any of the “methylation clocks”
necessarily curtail risks of age-related disease. This is a key question for a community of epidemiologists
who are eager for reliable markers of aging that can measure the benefits of their interventions without
waiting decades for morbidity and mortality to be measurably affected in experimental participants. For
clinicians who follow the current research, they will certainly want to know how much confidence to lend
to clinical studies in which the endpoint is methylation age.
3.5 Cautions and Future Directions
One significant limitation of this pilot trial is limited statistical power to due the relatively small sample
size. Confirmation of these results is therefore needed in larger study groups and populations beyond
middle-aged men.
The use of a multimodal intervention has advantages, as discussed above, however it also means that the
contributions of any one component to the overall potential benefit of the intervention cannot be
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
attributed to any individual element of the intervention. The combination of interventions used in this
study may yet be improved upon and may be more impactful when further personalized. Future iterations
of the intervention in continued clinical trials will attempt to optimize the program for efficacy,
efficiency, scalability and affordability. An ever-evolving understanding of personalized application of
such dietary and lifestyle interventions will likely lead to refinements to this kind of intervention that may
further extend indicators of biological age.
Finally, it may be that emerging “omics” approaches continue to evolve our understanding of biological
age prediction and reversal beyond DNA methylation alone (Lorusso et al., 2018). Integration of our
future understanding of multi-omics data should therefore be considered in the future trials of candidate
age-delaying interventions.
4. EXPERIMENTAL PROCEDURES
4.1 Study design and conduct
The trial design was approved by the Institutional Review Board of the National University of Natural
Medicine (IRB number: RB100217) and registered at ClinicalTrials.gov (Identifier: NCT03472820). All
trial procedures (visits, consent, randomization, and study visits) were conducted at the Helfgott Research
Institute, 2220 SW 1st Ave, Portland, OR 97201.
Participants were voluntarily recruited on a rolling basis from the general community surrounding
Portland, OR, using flyers, online and newspaper advertising, and electronic newsletters. Volunteers
completed telephone pre-screening followed by an initial onsite screening visit including confirmation of
eligibility, willingness to follow the study protocol, and informed consent.
43 eligible adult males without history of recent or chronic disease, between the ages of 50-72, were
recruited, consented, enrolled and randomized between March 2018 and August 2019. A CONSORT flow
diagram is shown in Figure 3. Baseline characteristics are shown in Table 1. The age range of 50-72 was
selected as a time when age-related vulnerabilities typically manifest, and the limitation to only male
participants was to avoid the potential confounding factor of pre-, peri-, and post-menopausal sex
hormone levels of the same age range in women.
A 3-week washout period (with written instruction) was initiated for all participants involving
discontinuation of any nutrition supplements or herbal products not prescribed by a licensed healthcare
provider for a medical condition. Allowable exceptions for dietary supplementation included low dose
supplements, such as a common "1-a-day" multivitamin/mineral (i.e. high potency, high dose
multivitamin/mineral products were not allowable), and/or other supplements taken for prevention: fish
oil (up to 1 gram/day), vitamin D (up to 6000 IU/day), vitamin C (up to 1g/day), vitamin E (up to 400
IU/day). Notably, these supplements were not recommended or prescribed, but participants already taking
these products were allowed to continue them during the trial, thus any effects would be captured in their
baseline assessments. Participants agreed to avoid/discontinue any recreational drugs/substances, as well
as to consume no alcohol, nicotine, marijuana or cannabinoids at least 1 week before scheduled study
visits.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Study participants were randomized at the baseline visit according to a randomization sequence
(randomization.com). Allocation concealment was accomplished by opening sealed, signed envelopes
prepared by research staff not associated with the trial which were only opened at randomization.
Initial instructions, including a recorded instructional webinar and electronic technology webinar were
provided at visit 1. To allow time for participant education to occur, participants in the treatment group
were instructed to begin the 8-week intervention protocol (including dietary, supplement, and lifestyle
changes) starting one week after the baseline visit. Saliva samples were collected at each of the three
study visits (baseline, week 5 and week 9).
An overview of the intervention is provided in Table 2. Two nutritional supplements (PhytoGanix® and
UltraFlora® Intensive Care, Metagenics Inc., 25 Enterprise Aliso Viejo, CA 92656 USA) were
distributed at visits 1 and 2. Unused doses were collected, counted and recorded at visits 2 and 3. Dosing
adherence was verified by the retrospective review of returned doses, direct queries about each
component of the intervention during study visits, and by frequent communication with trial participants.
Adherence to the program was supported by regular coaching sessions, delivered weekly during the first
four weeks, and then at least every other week thereafter. Coaching sessions followed a pre-defined script
that covered adherence to intervention guidelines and any changes to medications. A HIPAA-compliant
electronic technology coaching tool was offered (MBody360, 640 Broadway 5A, New York, NY 10012)
which contained reference instructions, meal planning ideas, optional recipes, and a shopping list.
Participants could also use this tool to communicate with their assigned coach in between scheduled
coaching sessions. Email, web platform and/or phone communication were other options for participants
unable or unwilling to use MBody360.
4.3 Determination of epigenetic age
Sample Handling: Saliva samples were stored at -70°C and remained frozen throughout the duration of
the trial. Frozen samples were batch shipped overnight on dry ice to Yale University Center for Genome
Analysis at the conclusion of clinical operations. Prior to shipment, sample IDs were assigned to plates
such that each plate included a representative collection of samples from both allocation groups
(treatment and control) and a distribution of samples from each trial visit, i.e., plates were not
homogenous by group or by visit type, in an effort to equally distribute any random variability resulting
from measurement across plates.
DNA Extraction: Oragene Saliva tubes were submitted and DNA extracted using the Perkin Elmer
Chemagic 360 Instrument (kit# CMG-1081) following the manufacturer’s recommended protocol. An
RNASE A digestion was added using 80uL of 4mg/uL Amercian Bioanalytical RNASE A
(Part#AB12023-00100) after the 50 degree Celsius Oragene Saliva Incubation, before loading samples
onto instrument.
Genomic DNA and RNA: The quality of the RNA/DNA was evaluated by: A260/A280 and A260/A230
ratios (as supplied by the NanoDrop 1000 Spectrophotometer), both of which should be > 1.8. The gel
electrophoresis pattern was consistent with non-degraded samples.
Methods: Sample DNA was normalized to the recommended starting concentration, 1ug, for the Zymo
EZ-96 DNA Methylation Kit (Cat No D5004). The samples underwent an overnight bisulfate conversion
and were purified using the Zymo Methylation protocol. Samples proceeded directly to the Illumina
Infinium HD assay (Illumina Methylation Epic Array Cat. No. WG-317-1001) to overnight whole
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
genome amplification at 37 degrees Celsius. The following day samples were fragmented for 1hour at 37
degrees, precipitated at 4 degrees for 30 minutes, and pelleted at 4 degrees for 20 minutes at 3000xg.
Samples were dried in a hood at room temperature for 1 hour and re-suspended in the recommended
volume of RA1 following Illumina’s Infinium HD assay at 48 degrees Celsius for 1 hour. Samples were
then denatured at 95 degrees Celsius for 20 minutes. Samples had a 10-minute cool down and then
directly hybridized to Illumina Methylation Epic Array Cat. No. WG-317-1001. Sample placement in
each chip was randomized. Hybridization was for 18 hours at 48 degrees Celsius using a stabilized
hybridization oven. The following day arrays were washed and stained automatically using the Tecan
Freedom Evo technology. Arrays were then be dipped in the UV protectant (Illumina’s XC3) for ten
minutes and any excess removed. Arrays were dried for 1 hour in a vacuum desiccator. Arrays were
scanned using Illumina’s iScan array scanner and raw files generated. Raw data files were imported into
Illumina’s GenomeStudio software and a project created as well as QC parameters checked to ensure
project went as expected. Scanned output files were analyzed and call rates calculated using Illumina’s
GenomeStudio. The quality of the data was evaluated by both sample dependent and sample independent
controls. Specifically, efficiency of target removal, non-specific binding, and appearance of cross-
contamination was examined. All raw Data and the GenomeStudio project were uploaded to the password
protected Keck Microarray Database.
Data Analysis: DNAmAge was calculated using the online Horvath clock available at
https://dnamage.genetics.ucla.edu/. Analysis of epigenetic age was performed, blinded, on the final 18
participants in the treatment group and 20 participants in the control group. P values were computed as an
unpaired 2-tailed t-test between the experimental group and control group, using the individual score
differences (after treatment minus before) as a random variable.
Data Sharing: The data that support the findings will be available in Gene Expression Omnibus at
https://www.ncbi.nlm.nih.gov/geo/, submission number GSE 149747, from 04-14-23 following an
embargo from the date of publication to allow for commercialization of research findings.
5 ACKNOWLEDGMENTS
We would like to acknowledge and thank the following for their assistance in this research study: The
team at the National University of Natural Medicine Helfgott Research Institute for conducting the
clinical trial. Kari Thostensen and MBody360 for their collaboration and the use of their coaching
platform. Marquelle Brown, Janine Henkel, Alison Parkerson and Brianne Pugh for their contributions to
diet-compatible recipe development. Yale University for measuring CpG site methylation according to
the Illumina Infinium array. Dr. Moshe Szyf’s team at the Department of Pharmacology and Therapeutics
at McGill University for their input on data analysis. Josh Mitteldorf for his extensive assistance with data
analysis. Steve Horvath PhD ScD, for input on the calculation of epigenetic age.
This study was generously supported through an unrestricted grant from Metagenics, Inc.
6 CONFLICT OF INTEREST
KF and RH declare that they use the intervention described here in clinical practice, are named in a
related patent application, and receive earnings from educational products associated with its use.
Notably, KF and RH were not involved in the day-to-day conduct of the trial, collection of samples, or
data analysis.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
7 AUTHOR CONTRIBUTIONS
KF, RB and MS designed the study. RH and KF designed the study diet. RB and ES conducted the
clinical trial at Helfgott Research Institute. JH, SL, JH, DG and MT coached the participants through the
intervention. DH performed the data analysis and reporting with MS, DC and DH in an advisory capacity.
KF, RB and RH developed the manuscript. All authors approved the manuscript.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
8 REFERENCES
Barja, G. (2019). Towards a unified mechanistic theory of aging. Experimental gerontology, 124, 110627.
Boyd-Kirkup, J. D., Green, C. D., Wu, G., Wang, D., & Han, J.-D. J. (2013). Epigenomics and the
regulation of aging. Epigenomics, 5(2), 205-227.
Carroll, J. E., Irwin, M. R., Levine, M., Seeman, T. E., Absher, D., Assimes, T., & Horvath, S. (2017).
Epigenetic aging and immune senescence in women with insomnia symptoms: findings from the
Women’s Health Initiative Study. Biological psychiatry, 81(2), 136-144.
Carskadon, M. A., Chappell, K. R., Barker, D. H., Hart, A. C., Dwyer, K., Gredvig-Ardito, C., . . .
McGeary, J. E. (2019). A pilot prospective study of sleep patterns and DNA methylation-
characterized epigenetic aging in young adults. BMC research notes, 12(1), 1-5.
Chen, B. H., Marioni, R. E., Colicino, E., Peters, M. J., Ward-Caviness, C. K., Tsai, P.-C., . . . Horvath, S.
(2016). DNA methylation-based measures of biological age: meta-analysis predicting time to
death. Aging (Albany NY), 8(9), 1844-1859. doi:10.18632/aging.101020
de Grey, A. D. (2005). The unfortunate influence of the weather on the rate of ageing: why human caloric
restriction or its emulation may only extend life expectancy by 2-3 years. Gerontology, 51(2), 73-
82. doi:10.1159/000082192
e Silva, A. d. S., & da Mota, M. P. G. (2014). Effects of physical activity and training programs on
plasma homocysteine levels: a systematic review. Amino acids, 46(8), 1795-1804.
Ebbing, M., Bonaa, K. H., Nygard, O., Arnesen, E., Ueland, P. M., Nordrehaug, J. E., . . . Vollset, S. E.
(2009). Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA,
302(19), 2119-2126. doi:10.1001/jama.2009.1622
Fahy, G. M., Brooke, R. T., Watson, J. P., Good, Z., Vasanawala, S. S., Maecker, H., . . . Horvath, S.
(2019). Reversal of epigenetic aging and immunosenescent trends in humans. Aging cell.
Field, A. E., Robertson, N. A., Wang, T., Havas, A., Ideker, T., & Adams, P. D. (2018). DNA
methylation clocks in aging: categories, causes, and consequences. Molecular cell, 71(6), 882-
895.
Figueiredo, J. C., Grau, M. V., Haile, R. W., Sandler, R. S., Summers, R. W., Bresalier, R. S., . . . Baron,
J. A. (2009). Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl
Cancer Inst, 101(6), 432-435. doi:10.1093/jnci/djp019
Goldman, D. (2017). THE ECONOMIC RETURNS TO DELAYED AGING: PROMISE AND
PITFALLS. Innovation in Aging, 1(Suppl 1), 1082.
Hariri, M., Salehi, R., Feizi, A., Mirlohi, M., Ghiasvand, R., & Habibi, N. (2015). A randomized, double-
blind, placebo-controlled, clinical trial on probiotic soy milk and soy milk: effects on epigenetics
and oxidative stress in patients with type II diabetes. Genes & nutrition, 10(6), 52.
Hayano, M., Yang, J.-H., Bonkowski, M. S., Amorim, J. A., Ross, J. M., Coppotelli, G., . . . Yang, X.
(2019). DNA Break-Induced Epigenetic Drift as a Cause of Mammalian Aging.
Hore, T. A. (2017). Modulating epigenetic memory through vitamins and TET: implications for
regenerative medicine and cancer treatment. Epigenomics, 9(6), 863-871.
Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome biology, 14(10),
R115.
Horvath, S., Oshima, J., Martin, G. M., Lu, A. T., Quach, A., Cohen, H., . . . Kabacik, S. (2018).
Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and
ex vivo studies. Aging (Albany NY), 10(7), 1758.
Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock theory of
ageing. Nature Reviews Genetics, 1.
Jin, K., Simpkins, J. W., Ji, X., Leis, M., & Stambler, I. (2015). The critical need to promote research of
aging and aging-related diseases to improve health and longevity of the elderly population. Aging
and disease, 6(1), 1.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Johnson, A. A., Akman, K., Calimport, S. R., Wuttke, D., Stolzing, A., & de Magalhães, J. P. (2012). The
Role of DNA Methylation in Aging, Rejuvenation, and Age-Related Disease. Rejuvenation
Research, 15(5), 483-494.
Kane, A. E., & Sinclair, D. A. (2019). Epigenetic changes during aging and their reprogramming
potential. Critical reviews in biochemistry and molecular biology, 54(1), 61-83.
Langie, S. A. S., Moisse, M., Declerck, K., Koppen, G., Godderis, L., Vanden Berghe, W., . . . De
Boever, P. (2017). Salivary DNA Methylation Profiling: Aspects to Consider for Biomarker
Identification. Basic Clin Pharmacol Toxicol, 121 Suppl 3, 93-101. doi:10.1111/bcpt.12721
Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., . . . Li, Y. (2018). An
epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY), 10(4), 573.
Li, E., & Zhang, Y. (2014). DNA methylation in mammals. Cold Spring Harbor perspectives in biology,
6(5), a019133.
Lorusso, J. S., Sviderskiy, O. A., & Labunskyy, V. M. (2018). Emerging Omics Approaches in Aging
Research. Antioxid Redox Signal, 29(10), 985-1002. doi:10.1089/ars.2017.7163
Mitteldorf, J. (2013). How does the body know how old it is? Introducing the epigenetic clock hypothesis.
Biochemistry (Moscow), 78(9), 1048-1053.
Moore, S. R., McEwen, L. M., Quirt, J., Morin, A., Mah, S. M., Barr, R. G., . . . Kobor, M. S. (2017).
Epigenetic correlates of neonatal contact in humans. Development and psychopathology, 29(5),
1517-1538.
Nilsson, E. K., Boström, A. E., Mwinyi, J., & Schiöth, H. B. (2016). Epigenomics of total acute sleep
deprivation in relation to genome-wide DNA methylation profiles and RNA expression. Omics: a
journal of integrative biology, 20(6), 334-342.
Obeid, R., Hubner, U., Bodis, M., Graeber, S., & Geisel, J. (2018). Effect of adding B-vitamins to vitamin
D and calcium supplementation on CpG methylation of epigenetic aging markers. Nutr Metab
Cardiovasc Dis, 28(4), 411-417. doi:10.1016/j.numecd.2017.12.006
Oliai Araghi, S., Kiefte-de Jong, J. C., van Dijk, S. C., Swart, K. M. A., van Laarhoven, H. W., van
Schoor, N. M., . . . van der Velde, N. (2019). Folic Acid and Vitamin B12 Supplementation and
the Risk of Cancer: Long-term Follow-up of the B Vitamins for the Prevention of Osteoporotic
Fractures (B-PROOF) Trial. Cancer Epidemiol Biomarkers Prev, 28(2), 275-282.
doi:10.1158/1055-9965.EPI-17-1198
Pal, S., & Tyler, J. K. (2016). Epigenetics and aging. Science advances, 2(7), e1600584.
Panel, C. C., Watson, N. F., Badr, M. S., Belenky, G., Bliwise, D. L., Buxton, O. M., . . . Grandner, M. A.
(2015). Joint consensus statement of the American Academy of Sleep Medicine and Sleep
Research Society on the recommended amount of sleep for a healthy adult: methodology and
discussion. Sleep, 38(8), 1161-1183.
Pauwels, S., Ghosh, M., Duca, R. C., Bekaert, B., Freson, K., Huybrechts, I., . . . Godderis, L. (2017).
Maternal intake of methyl-group donors affects DNA methylation of metabolic genes in infants.
Clin Epigenetics, 9. doi:10.1186/s13148-017-0321-y
Pavanello, S., Campisi, M., Tona, F., Dal Lin, C., & Iliceto, S. (2019). Exploring Epigenetic Age in
Response to Intensive Relaxing Training: A Pilot Study to Slow Down Biological Age.
International journal of environmental research and public health, 16(17), 3074.
Quach, A., Levine, M. E., Tanaka, T., Lu, A. T., Chen, B. H., Ferrucci, L., . . . Beasley, J. M. (2017).
Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. Aging (Albany NY),
9(2), 419.
Rando, T. A., & Chang, H. Y. (2012). Aging, rejuvenation, and epigenetic reprogramming: resetting the
aging clock. Cell, 148(1), 46-57.
Ren, H., Collins, V., Clarke, S. J., Han, J.-S., Lam, P., Clay, F., . . . Andy Choo, K. (2012). Epigenetic
changes in response to tai chi practice: a pilot investigation of DNA methylation marks.
Evidence-based Complementary and Alternative Medicine, 2012.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Sae-Lee, C., Corsi, S., Barrow, T. M., Kuhnle, G. G. C., Bollati, V., Mathers, J. C., & Byun. (2018).
Dietary Intervention Modifies DNA Methylation Age Assessed by the Epigenetic Clock.
Molecular nutrition & food research, 62(23). doi:10.1002/mnfr.201800092
Sen, P., Shah, P. P., Nativio, R., & Berger, S. L. (2016). Epigenetic mechanisms of longevity and aging.
Cell, 166(4), 822-839.
Spólnicka, M., Po piech, E., Adamczyk, J. G., Freire-Aradas, A., Pepło ska, B., Zbie -Piekarska, R., . . .
Phillips, C. (2018). Modified aging of elite athletes revealed by analysis of epigenetic age
markers. Aging (Albany NY), 10(2), 241.
Sybesma, W., Starrenburg, M., Tijsseling, L., Hoefnagel, M. H., & Hugenholtz, J. (2003). Effects of
cultivation conditions on folate production by lactic acid bacteria. Appl. Environ. Microbiol.,
69(8), 4542-4548.
Tu, H., Dinney, C. P., Ye, Y., Grossman, H. B., Lerner, S. P., & Wu. (2018). Is Folic Acid Safe for Non-
Muscle-Invasive Bladder Cancer Patients? An Evidence-Based Cohort Study. The American
journal of clinical nutrition, 107(2). doi:10.1093/ajcn/nqx019
van Wijngaarden, J. P., Swart, K. M., Enneman, A. W., Dhonukshe-Rutten, R. A., van Dijk, S. C., Ham,
A. C., . . . de Groot, L. C. (2014). Effect of daily vitamin B-12 and folic acid supplementation on
fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-
PROOF, a randomized controlled trial. Am J Clin Nutr, 100(6), 1578-1586.
doi:10.3945/ajcn.114.090043
Waterland, R. A., & Jirtle, R. L. (2003). Transposable elements: targets for early nutritional effects on
epigenetic gene regulation. Molecular and cellular biology, 23(15), 5293-5300.
West, M. D., Sternberg, H., Labat, I., Janus, J., Chapman, K. B., Malik, N. N., . . . Larocca, D. (2019).
Toward a unified theory of aging and regeneration. Regenerative medicine, 14(9), 867-886.
White, A. J., Sandler, D. P., Bolick, S. C., Xu, Z., Taylor, J. A., & DeRoo, L. A. (2013). Recreational and
household physical activity at different time points and DNA global methylation. European
journal of cancer, 49(9), 2199-2206.
Wolf, E. J., Logue, M. W., Hayes, J. P., Sadeh, N., Schichman, S. A., Stone, A., . . . Miller, M. W. (2016).
Accelerated DNA methylation age: associations with PTSD and neural integrity.
Psychoneuroendocrinology, 63, 155-162.
Zannas, A. S., Arloth, J., Carrillo-Roa, T., Iurato, S., Röh, S., Ressler, K. J., . . . Heim, C. (2015).
Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of
glucocorticoid signaling. Genome biology, 16(1), 266.
Zhong, J., Karlsson, O., Wang, G., Li, J., Guo, Y., Lin, X., . . . Baccarelli, A. A. (2017). B vitamins
attenuate the epigenetic effects of ambient fine particles in a pilot human intervention trial. Proc
Natl Acad Sci U S A, 114(13), 3503-3508. doi:10.1073/pnas.1618545114
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Figure 1.
Comparison of DNAmAge change between treatment and control groups. Each dot is a subject, and the vertical
axis represents difference in DNAmAge from the beginning to the end of the eight-week term. Participants scored an average
1.96 years younger, controls an average 1.27 years older. The age reduction of the treatment group strongly trended towards
significance (p=0.066), while the age increase of the control group itself was not significant (p=0.153). The difference between
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
control and treatment groups was significant at the level p=0.018 (unpaired two-tailed t-test). Long red and blue lines represent
group averages (mean).
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Figure 2.
Intervention group age change. Participants scored an average of 1.96 years younger than baseline (p=0.066). Of
18 participants included in the final analysis, 8 scored age reduction, 9 were unchanged, and 1 increased in methylation age.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Assessed for eligibility (n=
3
)
Excluded (n=
8
9
)
Not meeting inclusion criteria (n=57)
Declined to participate (n=22)
Other reasons (n=10)
Analy
s
ed (n=
)
Excluded from analysis (Participants did not
complete the intervention) (n=4)
Lost to follow
-
up (n=
0
)
Discontinued intervention (Participants
withdrew due to lack of interest in continuing)
(n=4)
Al
l
ocated to intervention (n=
)
Received allocated intervention (n=22)
Did not receive allocated intervention
(allocated to control) (n=22)
Lost to follow
-
up (n=
0
)
Discontinued control (Participants withdrawn
due to change that violated protocol) (n=2)
Allocated to
control
(n=
)
Received allocated control (n=22)
Did not receive allocated control (allocated to
intervention) (n=22)
Analysed (n=
)
Excluded from analysis (Participants did not
complete the study) (n=2)
Randomized (n=
)
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Characteristics
Treatment Group
n = 21 Control Group
n = 22
Value % Value %
Age, years (mean ±SD) 58.5 ± 6.12 60.3 ± 6.68
Race
Black or African American 0 0 2 9.1
American Indian or Native Alaskan 0 0 0 0
Native Hawaiian or Other Pacific Islander 0 0 0 0
Asian or Asian American 3 13.6 1 4.5
White, Caucasian or European American 18 81.8 18 81.8
Caribbean Islander or African National 0 0 0 0
More than one race 0 0 1 4.5
Unknown 0 0 0 0
Education Level
Some high school 0 0 0 0
High school 0 0.00 3 0.14
Some university 1 0.05 1 0.05
2 year university 2 0.09 1 0.05
4 year university 6 0.27 4 0.18
Some graduate school 2 0.09 4 0.18
Graduate degree 11 0.50 9 0.41
Table 1: Baseline characteristics
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
Intervention Category Details
Dietary Prescription Guidance per week:
3 servings of liver
(1 serving = 3 oz)
Preferably organic
5-10 eggs
Ideally free-range, organic, omega-3 enriched
Guidance per day:
2 cups of dark leafy greens
Measured raw, chopped, and packed
Including kale, Swiss chard, collards, spinach, dandelion,
mustard greens
Does not include salad greens such as romaine, iceberg,
Spring mix
2 cups cruciferous vegetables
Measured raw, chopped, and packed
Includes broccoli, cabbage, cauliflower, Brussels sprouts,
bok choy, arugula, kale, mustard greens, watercress,
rutabaga, kohlrabi, radish, Swiss chard, turnip
3 additional cups colorful vegetables of your choosing
(excluding white potatoes, sweetcorn)
1-2 medium beet
4 tbsp (1/4 cup) pumpkin seeds (or pumpkin seed butter)
4 tbsp (1/4 cup) sunflower seeds (or sunflower seed butter)
1+ serving methylation adaptogens, choose from:
1/2 cup berries (wild preferred)
1/2 tsp rosemary
1/2 tsp turmeric
2 medium cloves garlic
2 cups green tea (brewed 10 minutes)
3 cups oolong tea (brewed 10 minutes)
6 oz animal protein
Grass-fed, pastured, organic and hormone/antibiotic-free
2 servings of low glycemic fruit
General guidance:
Organic preferred over conventional
Stay hydrated
Don’t eat between 7pm and 7am
Include “healthy” oils
Balance types of fat
E.g. coconut, olive, flaxseed and pumpkin seed oil
Avoid added sugar/candy, dairy, grains, legumes/beans
Minimize plastic food containers
Supplement Prescription PhytoGanix®, a combination of organic vegetables, fruits, seeds,
herbs, plant enzymes, prebiotics and probiotics at a dose of 2
servings daily, divided
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
UltraFlora® Intensive Care, containing Lactobacillus plantarum
299v at a dose of 2 capsules daily, divided
Exercise Prescription Minimum of 30 minutes of exercise per day for at least 5 days per
week, at an intensity of 60-80% of maximum perceived exertion
Sleep Prescription Average a minimum of 7 hours of sleep per night
Stress Management Prescription
A
Breathing exercise Steps to Elicit the Relaxation Response
developed by Herbert Benson MD, twice daily
Table 2: Summary of Dietary and Lifestyle Interventions*. AStress Management Recommendations were
updated from the original Study Protocol as listed on ClinicalTrials.gov. All updates were IRB approved.
*Patent pending.
. CC-BY-NC-ND 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.07.20148098doi: medRxiv preprint
... These criteria best facilitate the selection of a marker that measures the effectiveness of interventions on biological age reversal. Until recently, the possibility of biological age reversal was uncertain, but thanks to recent experimental trials utilizing biological age predictors we now know that biological age as measured by biomarkers of aging can be slowed or even reversed (Fahy et al., 2019;Fitzgerald et al., 2020;Hachmo et al., 2020). With that in mind, our specific aim is to compile the available evidence related to various readily accessible biological age predictors. ...
Article
Full-text available
As healthspan and lifespan research breakthroughs have become more commonplace, the need for valid, practical markers of biological age is becoming increasingly paramount. The accessibility and affordability of biological age predictors that can reveal information about mortality and morbidity risk, as well as remaining years of life, has profound clinical and research implications. In this review, we examine 5 groups of aging biomarkers capable of providing accurate biological age estimations. The unique capabilities of these biomarkers have far reaching implications for the testing of both pharmaceutical and non-pharmaceutical interventions designed to slow or reverse biological aging. Additionally, the enhanced validity and availability of these tools may have increasingly relevant clinical value. The authors of this review explore those implications, with an emphasis on lifestyle modification research, and provide an overview of the current evidence regarding 5 biological age predictor categories: Telomere length, composite biomarkers, DNA methylation “epigenetic clocks,” transcriptional predictors of biological age, and functional age predictors.
Article
Full-text available
Psychopathology is a risk factor for accelerated biological aging and early mortality. We examined associations between broad underlying dimensions of psychopathology (reflecting internalizing and externalizing psychiatric symptoms), PTSD, and age-adjusted GrimAge ("GrimAge residuals"), a DNA methylation biomarker of mortality risk relative to age. We also examined neurobiological correlates of GrimAge residuals, including neurocognitive functioning, blood-based biomarkers (of inflammation, neuropathology, metabolic disease), and cortical thickness. Data from two independent trauma-exposed military cohorts (n = 647 [62.9% male, Mage=52], n = 434 [90% male, Mage=32]) were evaluated using linear regression models to test associations between GrimAge residuals, psychopathology, and health correlates. Externalizing psychopathology significantly predicted GrimAge residuals in both cohorts (ps<.028). PTSD predicted GrimAge residuals in the younger (p=.001), but not older cohort. GrimAge residuals were associated with several neurobiological variables available in the younger cohort, including cognitive disinhibition (padj=.021), poorer memory recall (padj=.023), cardiometabolic pathology (padj<.001), oxidative stress (padj=.003), astrocyte damage (padj=.021), inflammation (C-reactive protein: padj<.001; IL-6: padj<.001), and immune functioning (padj<.001). A subset of inflammatory and neuropathology analytes were available in the older cohort and showed associations with GrimAge residuals (IL-6: padj<.001; TNF-α: padj<.001). GrimAge residuals were also associated with reduced cortical thickness in right lateral orbitofrontal cortex (padj=.018) and left fusiform gyrus (padj=.030), which are related to emotion regulation and facial recognition, respectively. Psychopathology may be a common risk factor for elevated mortality risk. GrimAge could help identify those at risk for adverse health outcomes and allow for early disease identification and treatment.
Article
Full-text available
Objective: Molecular markers in DNA methylation at a subset of CpG sites are affected by the environment and contribute to biological (epigenetic) age. We hypothesized that shorter sleep duration and possibly irregular sleep would be associated with accelerated epigenetic aging. We examined epigenetic vs. chronological age in 12 young women selected as shorter or longer sleepers studied prospectively across the first 9 weeks of college using a daily online sleep log. Genomic DNA was isolated from two blood samples spanning the interval, and DNA methylation levels were determined and used to measure epigenetic age. Results: Epigenetic vs. chronological age differences averaged 2.07 at Time 1 and 1.21 at Time 2. Sleep duration was computed as average daily total sleep time and sleep regularity was indexed using the Sleep Regularity Index. Participants with longer and more regular sleep showed reduced age difference: mean = - 2.48 [95% CI - 6.11; 1.15]; those with shorter and more irregular sleep showed an increased age difference: 3.03 [0.02; 6.03]; and those with either shorter or more irregular sleep averaged no significant change: - 0.49 [- 3.55; 2.56]. These pilot data suggest that short and irregular sleep, even in a young healthy sample, may be associated with accelerated epigenetic aging.
Article
Full-text available
Epigenetic "clocks" can now surpass chronological age in accuracy for estimating biological age. Here, we use four such age estimators to show that epigenetic aging can be reversed in humans. Using a protocol intended to regenerate the thymus, we observed protective immunological changes, improved risk indices for many age-related diseases, and a mean epigenetic age approximately 1.5 years less than baseline after 1 year of treatment (-2.5-year change compared to no treatment at the end of the study). The rate of epigenetic aging reversal relative to chronological age accelerated from -1.6 year/year from 0-9 month to -6.5 year/year from 9-12 month. The GrimAge predictor of human morbidity and mortality showed a 2-year decrease in epigenetic vs. chronological age that persisted six months after discontinuing treatment. This is to our knowledge the first report of an increase, based on an epigenetic age estimator, in predicted human lifespan by means of a currently accessible aging intervention.
Article
Full-text available
Growing evidence supports the antagonistic pleiotropy theory of mammalian aging. Accordingly, changes in gene expression following the pluripotency transition, and subsequent transitions such as the embryonic–fetal transition, while providing tumor suppressive and antiviral survival benefits also result in a loss of regenerative potential leading to age-related fibrosis and degenerative diseases. However, reprogramming somatic cells to pluripotency demonstrates the possibility of restoring telomerase and embryonic regeneration pathways and thus reversing the age-related decline in regenerative capacity. A unified model of aging and loss of regenerative potential is emerging that may ultimately be translated into new therapeutic approaches for establishing induced tissue regeneration and modulation of the embryo-onco phenotype of cancer.
Article
Full-text available
DNA methylation (DNAm) is an emerging estimator of biological aging, i.e., the often-defined “epigenetic clock”, with a unique accuracy for chronological age estimation (DNAmAge). In this pilot longitudinal study, we examine the hypothesis that intensive relaxing training of 60 days in patients after myocardial infarction and in healthy subjects may influence leucocyte DNAmAge by turning back the epigenetic clock. Moreover, we compare DNAmAge with another mechanism of biological age, leucocyte telomere length (LTL) and telomerase. DNAmAge is reduced after training in healthy subjects (p = 0.053), but not in patients. LTL is preserved after intervention in healthy subjects, while it continues to decrease in patients (p = 0.051). The conventional negative correlation between LTL and chronological age becomes positive after training in both patients (p < 0.01) and healthy subjects (p < 0.05). In our subjects, DNAmAge is not associated with LTL. Our findings would suggest that intensive relaxing practices influence different aging molecular mechanisms, i.e., DNAmAge and LTL, with a rejuvenating effect. Our study reveals that DNAmAge may represent an accurate tool to measure the effectiveness of lifestyle-based interventions in the prevention of age-related diseases.
Article
Full-text available
Background Folic acid and vitamin B12 play key roles in one-carbon metabolism. Disruption of one-carbon metabolism may be involved in the risk of cancer. Our aim was to assess the long-term effect of supplementation with both folic acid and vitamin B12 on the incidence of overall cancer and on colorectal cancer in the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) trial. Methods Long-term follow-up of B-PROOF trial participants (N = 2,524), a multicenter, double-blind randomized placebo-controlled trial designed to assess the effect of 2 to 3 years daily supplementation with folic acid (400 μg) and vitamin B12 (500 μg) versus placebo on fracture incidence. Information on cancer incidence was obtained from the Netherlands cancer registry (Integraal Kankercentrum Nederland), using the International Statistical Classification of Disease (ICD-10) codes C00–C97 for all cancers (except C44 for skin cancer), and C18–C20 for colorectal cancer. Results Allocation to B vitamins was associated with a higher risk of overall cancer [171 (13.6%) vs. 143 (11.3%); HR 1.25; 95% confidence interval (CI), 1.00–1.53, P = 0.05]. B vitamins were significantly associated with a higher risk of colorectal cancer [43(3.4%) vs. 25(2.0%); HR 1.77; 95% CI, 1.08–2.90, P = 0.02]. Conclusions Folic acid and vitamin B12 supplementation was associated with an increased risk of colorectal cancer. Impact Our findings suggest that folic acid and vitamin B12 supplementation may increase the risk of colorectal cancer. Further confirmation in larger studies and in meta-analyses combining both folic acid and vitamin B12 are needed to evaluate whether folic acid and vitamin B12 supplementation should be limited to patients with a known indication, such as a proven deficiency.
Article
Full-text available
DNA methylation (DNAm)-based biomarkers of aging have been developed for many tissues and organs. However, these biomarkers have sub-optimal accuracy in fibroblasts and other cell types used in ex vivo studies. To address this challenge, we developed a novel and highly robust DNAm age estimator (based on 391 CpGs) for human fibroblasts, keratinocytes, buccal cells, endothelial cells, lymphoblastoid cells, skin, blood, and saliva samples. High age correlations can also be observed in sorted neurons, glia, brain, liver, and even bone samples. Gestational age correlates with DNAm age in cord blood. When used on fibroblasts from Hutchinson Gilford Progeria Syndrome patients, this age estimator (referred to as the skin & blood clock) uncovered an epigenetic age acceleration with a magnitude that is below the sensitivity levels of other DNAm-based biomarkers. Furthermore, this highly sensitive age estimator accurately tracked the dynamic aging of cells cultured ex vivo and revealed that their proliferation is accompanied by a steady increase in epigenetic age. The skin & blood clock predicts lifespan and it relates to many age-related conditions. Overall, this biomarker is expected to become useful for forensic applications (e.g. blood or buccal swabs) and for a quantitative ex vivo human cell aging assay.
Article
The aging process results in significant epigenetic changes at all levels of chromatin and DNA organization. These include reduced global heterochromatin, nucleosome remodeling and loss, changes in histone marks, global DNA hypomethylation with CpG island hypermethylation, and the relocalization of chromatin modifying factors. Exactly how and why these changes occur is not fully understood, but evidence that these epigenetic changes affect longevity and may cause aging, is growing. Excitingly, new studies show that age-related epigenetic changes can be reversed with interventions such as cyclic expression of the Yamanaka reprogramming factors. This review presents a summary of epigenetic changes that occur in aging, highlights studies indicating that epigenetic changes may contribute to the aging process and outlines the current state of research into interventions to reprogram age-related epigenetic changes.
Article
Age-associated changes to the mammalian DNA methylome are well documented and thought to promote diseases of aging, such as cancer. Recent studies have identified collections of individual methylation sites whose aggregate methylation status measures chronological age, referred to as the DNA methylation clock. DNA methylation may also have value as a biomarker of healthy versus unhealthy aging and disease risk; in other words, a biological clock. Here we consider the relationship between the chronological and biological clocks, their underlying mechanisms, potential consequences, and their utility as biomarkers and as targets for intervention to promote healthy aging and longevity.